SUPPORT-T palliative program for people with progressive pulmonary fibrosis and their caregivers
Official title: Feasibility and Acceptability of a Mobile Application "SUPPORT-T" to Increase Equitable Access to Palliative Care in Patients With Progressive Pulmonary Fibrosis (PPF) and Their Caregivers
Run by Medical University of South Carolina · NCT07269262 · Data updated 2026-11-12
This pilot tests a 9-week digital palliative care program plus quarterly virtual support groups to see if it helps adults with progressive pulmonary fibrosis and their caregivers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 170 (estimated) |
| Sponsor | Medical University of South Carolina Academic / other |
| Locations | 1 site (Charleston, South Carolina) |
| Status | Recruiting |
| Started | January 13, 2026 |
| Main results expected | August 31, 2027 |
| Study ends | October 1, 2027 |
| Registry record updated | September 11, 2026 |
| Trial ID | NCT07269262 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a confirmed diagnosis of progressive pulmonary fibrosis who speak English or Spanish and can identify a willing adult caregiver (who understands English) are ideal candidates.
✕Probably not a fit
Patients without reliable internet access or comfort using digital apps, those without an English-speaking caregiver, or those with urgent medical instability may not benefit from this digitally delivered program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot randomized controlled trial compares SUPPORT-T, a 9-week digital application guided by a nurse interventionist with quarterly virtual support groups over one year, to Enhanced Usual Care for patients with progressive pulmonary fibrosis and their caregivers. Participants are recruited from rural South Carolina and urban New York City and randomized to intervention or control to test feasibility, acceptability, and accessibility. Identified caregivers are invited to participate alongside patients, and study procedures are delivered remotely with nurse facilitation. Results will inform the design of a future multi-site trial.
Why it matters
Potential benefit: If successful, SUPPORT-T could increase access to palliative support, improve symptom management and caregiver coping, and reduce isolation for people with progressive pulmonary fibrosis.
How similar studies have gone: Previous pilot and feasibility studies of digital or nurse-led palliative interventions in chronic lung disease or advanced illness have shown promise, but randomized data specifically in progressive pulmonary fibrosis are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥18 years * Confirmed diagnosis of PPF * English or Spanish speaking Caregiver Inclusion Criteria: * adult, ≥ 18 years old * Designated and identified by patient as providing most of the emotional, financial, and/or physical support (i.e., the individual most involved in care, does not have to live with patient) * Able to speak and understand English. Exclusion Criteria: \-
Where it's running
-
Medical University of South Carolina
Charleston, South Carolina, United States Recruiting
Study contacts
- Study coordinator: Kathleen Lindell, PhD, RN, ATSF, FAAN
- Email: lindellk@musc.edu
- Phone: (843) 792-9763
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis
A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.
-
Observational study on progressive pulmonary fibrosis and its classification
This study is trying to better understand and classify progressive pulmonary fibrosis in people with certain lung diseases by following them over two years and collecting their health information and blood samples.
-
Evaluating inhaled treprostinil for progressive pulmonary fibrosis
This study is testing if inhaled treprostinil can help people with progressive pulmonary fibrosis breathe better and live longer compared to a placebo.
-
Registry for individuals affected by pulmonary fibrosis
This study invites people with pulmonary fibrosis, along with their caregivers and family members, to share their experiences through online surveys to help researchers understand the condition better and possibly reach out for future studies.
-
Nerandomilast in IPF and Progressive Fibrosis: Real-World Data
This study tests whether nerandomilast helps slow lung function decline in adults with IPF or progressive fibrotic lung disease in routine clinical care.
-
Telitacicept for primary Sjögren’s with interstitial lung disease
This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.